These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35920102)

  • 1. Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
    Tanaka Y; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Combe BG; Kivitz AJ; Bae SC; Keystone EC; Nash P; Genovese M; Matzkies F; Bartok B; Pechonkina A; Kondo A; Ye L; Gong Q; Tasset C; Takeuchi T
    Mod Rheumatol; 2023 Jul; 33(4):668-679. PubMed ID: 35920102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
    Westhovens R; Rigby WFC; van der Heijde D; Ching DWT; Stohl W; Kay J; Chopra A; Bartok B; Matzkies F; Yin Z; Guo Y; Tasset C; Sundy JS; Jahreis A; Mozaffarian N; Messina OD; Landewé RB; Atsumi T; Burmester GR
    Ann Rheum Dis; 2021 Jun; 80(6):727-738. PubMed ID: 33452004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
    Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
    Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
    Atsumi T; Tanaka Y; Matsubara T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Westhovens R; Ching DWT; Messina OD; Burmester GR; Genovese M; Bartok B; Pechonkina A; Kondo A; Yin Z; Gong Q; Tasset C; Takeuchi T
    Mod Rheumatol; 2023 Jul; 33(4):657-667. PubMed ID: 35921235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
    Aletaha D; Westhovens R; Gaujoux-Viala C; Adami G; Matsumoto A; Bird P; Messina OD; Buch MH; Bartok B; Yin Z; Guo Y; Hendrikx T; Burmester GR
    RMD Open; 2021 Aug; 7(2):. PubMed ID: 34385364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
    Combe BG; Tanaka Y; Buch MH; Nash P; Burmester GR; Kivitz AJ; Bartok B; Pechonkina A; Xia K; Emoto K; Kano S; Hendrikx TK; Landewé RBM; Aletaha D
    Rheumatol Ther; 2023 Feb; 10(1):53-70. PubMed ID: 36209441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
    Tanaka Y; Atsumi T; Aletaha D; Bartok B; Pechonkina A; Han L; Emoto K; Kano S; Rajendran V; Takeuchi T
    Rheumatol Ther; 2023 Feb; 10(1):161-185. PubMed ID: 36327094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
    Tanaka Y; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Combe BG; Kivitz AJ; Bae SC; Keystone EC; Nash P; Matzkies F; Bartok B; Pechonkina A; Kondo A; Ye L; Guo Y; Tasset C; Sundy JS; Takeuchi T
    Mod Rheumatol; 2022 Feb; 32(2):263-272. PubMed ID: 34910188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
    Winthrop KL; Tanaka Y; Takeuchi T; Kivitz A; Matzkies F; Genovese MC; Jiang D; Chen K; Bartok B; Jahreis A; Besuyen R; Burmester GR; Gottenberg JE
    Ann Rheum Dis; 2022 Feb; 81(2):184-192. PubMed ID: 34740884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
    Atsumi T; Tanaka Y; Matsubara T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Westhovens R; Ching DWT; Messina OD; Burmester GR; Bartok B; Pechonkina A; Kondo A; Yin Z; Guo Y; Tasset C; Sundy JS; Takeuchi T
    Mod Rheumatol; 2022 Feb; 32(2):273-283. PubMed ID: 34910203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
    Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
    Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
    Ishiguro N; Tanaka Y; Matsubara T; Atsumi T; Amano K; Sugiyama E; Yamaoka K; Winthrop K; Kivitz A; Burmester GR; Gottenberg JE; Genovese MC; Matzkies F; Guo Y; Jiang D; Bartok B; Pechonkina A; Kondo A; Besuyen R; Takeuchi T
    Mod Rheumatol; 2023 Jan; 33(1):64-72. PubMed ID: 35365828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate.
    Buch MH; Walker D; Edwards CJ; Barry J; Akroyd L; Omoruyi EVE; Taylor PC
    Rheumatology (Oxford); 2024 Sep; ():. PubMed ID: 39331638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH; Song GG
    Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
    Takeuchi T; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Genovese MC; Kalunian K; Walker D; Gottenberg JE; de Vlam K; Bartok B; Pechonkina A; Kondo A; Gao J; Guo Y; Tasset C; Sundy JS; Tanaka Y
    Mod Rheumatol; 2022 Jan; 32(1):59-67. PubMed ID: 33274687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis.
    Curtis JR; Emery P; Downie B; Zhong Y; Liu J; Han L; Hawtin RE; Burmester GR
    Rheumatol Ther; 2024 Feb; 11(1):177-189. PubMed ID: 38057656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.